New technologies and digital transformation offer biopharmaceutical and medtech companies opportunities across their organizations—from how they conduct research and interact with regulators to how they optimize their finance, supply chains, and manufacturing operations. New digital capabilities can also change the game in how companies engage with their customers, patients, and other stakeholders. However, life sciences companies have not traditionally been early adopters of new technologies. What is holding life sciences companies back? How can they better take advantage of new digital capabilities? And how do they demonstrate impact and ROI from their investments?